{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T02:35:59Z","timestamp":1790562959611,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This meta-analysis aims to evaluate the effectiveness and safety of combining echinocandins with standard of care (SOC) antifungal drugs for treating invasive aspergillosis infection (IAI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We searched PubMed, Embase, and Cochrane Library from their inception to 25 July 2024. Our outcomes included clinical cure, mortality, and adverse drug reactions (ADRs). We compared echinocandins in combination with SOC antifungal agents against SOC monotherapy therapy. We used the random-effects model for the meta-analysis, and our estimated effects were reported as odds ratios (ORs) with 95% confidence intervals (CI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ten studies were included in our meta-analysis comprising 1100 patients: 415 were in the echinocandin combination groups, and 685 were in the SOC groups. The clinical cure rate (OR 1.35, 95% CI: 0.75\u20132.42, <jats:italic>p<\/jats:italic> = 0.27), mortality (OR 0.90, 95% CI: 0.50\u20131.63, <jats:italic>p<\/jats:italic> = 0.73), and ADRs rate (OR 0.95, 95% CI: 0.49\u20131.82, <jats:italic>p<\/jats:italic> = 0.87) were not statistically different in echinocandins combination with SOC compared to SOC monotherapy. Notably, there is a signal for a better clinical cure rate in echinocandins in combination with SOC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our meta-analysis found no differences in clinical cure and mortality rate when using combination therapy of echinocandin antifungal agents with the SOC compared to SOC monotherapy. However, there is a signal for better outcomes with the echinocandins combination group. The ADRs in the echinocandins combination group were not worse than SOC monotherapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1500529","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:41:04Z","timestamp":1734615664000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yazed Saleh","family":"Alsowaida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bader","family":"Alshoumr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuroug A.","family":"Alowais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Bin Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Alshammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareemah","family":"Alshurtan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haytham A.","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.23109","article-title":"Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial)","volume":"110","author":"Caillot","year":"2007","journal-title":"Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.diii.2015.01.005","article-title":"Pulmonary aspergillosis","volume":"96","author":"Chabi","year":"2015","journal-title":"Diagn Interv. Imaging"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin. Trials"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1128\/AAC.01111-12","article-title":"Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis","volume":"56","author":"Jeans","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw172.1331","article-title":"Combination antifungal therapy for invasive aspergillosis among patients with hematopoietic cell transplantation and positive galactomannan","volume":"3","author":"John","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.11479","article-title":"Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies","volume":"98","author":"Kontoyiannis","year":"2003","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"220114","DOI":"10.1183\/16000617.0114-2022","article-title":"Pulmonary aspergillosis: diagnosis and treatment","volume":"31","author":"Lamoth","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12879-024-09477-9","article-title":"Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Infect. Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1086\/423380","article-title":"Combination antifungal therapy for invasive aspergillosis","volume":"39","author":"Marr","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1002\/cncr.25312","article-title":"Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?","volume":"116","author":"Mihu","year":"2010","journal-title":"Cancer"},{"key":"B17","unstructured":"ClinicalTrials.gov azole-echinocandin combination Therapy for invasive aspergillosis (IA-DUET)\n          \n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2009.012054","article-title":"Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study","volume":"95","author":"Pagano","year":"2010","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00305-17","article-title":"Combination therapy with isavuconazole and micafungin for treatment of experimental invasive pulmonary aspergillosis","volume":"61","author":"Petraitis","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/sj.leu.2405065","article-title":"Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin","volume":"22","author":"Raad","year":"2008","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijantimicag.2014.08.012","article-title":"Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies","volume":"45","author":"Raad","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1016\/j.ijid.2012.09.004","article-title":"Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: fungal InfectioN Database (FIND) analysis, 2005-2009","volume":"17","author":"Racil","year":"2013","journal-title":"Int. J. Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/01.tp.0000202421.94822.f7","article-title":"Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study","volume":"81","author":"Singh","year":"2006","journal-title":"Transplantation"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"Jama"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/NEJMra2027424","article-title":"Aspergillus infections","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"835092","DOI":"10.3389\/fpubh.2022.835092","article-title":"Epidemiology, drug susceptibility, and clinical risk factors in patients with invasive aspergillosis","volume":"10","author":"Wang","year":"2022","journal-title":"Front. Public Health"},{"key":"B30","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analysesAvailable online\n          \n          \n            \n              Wells\n              G. S.\n            \n            \n              B; O'Connell\n              D.\n            \n            \n              Peterson\n              J.\n            \n            \n              Welch\n              V.\n            \n            \n              Losos\n              M.\n            \n            \n              Tugwell\n              P.\n            \n          \n          \n          2024"},{"key":"B31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3978\/j.issn.2072-1439.2014.01.18","article-title":"Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studies","volume":"6","author":"Zhang","year":"2014","journal-title":"J. Thorac. Dis."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1500529\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:41:08Z","timestamp":1734615668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1500529\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1500529"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1500529","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"article-number":"1500529"}}